{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:59:58Z","timestamp":1791406798042,"version":"4.3.3"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1124\/jpet.104.082966","type":"journal-article","created":{"date-parts":[[2005,5,17]],"date-time":"2005-05-17T18:51:51Z","timestamp":1116355911000},"page":"1150-1162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["In Vivo Characterization of 6\u03b2-Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice"],"prefix":"10.1016","volume":"313","author":[{"given":"Kirsten M.","family":"Raehal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Lowery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Castigliano M.","family":"Bhamidipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan M.","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Blair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Sad\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Bilsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.104.082966_bib1","doi-asserted-by":"crossref","unstructured":"Barsan WG, Seger D, Danzl DF, Ling LJ, Bartlett R, Buncher R, and Bryan C (1989) Duration of antagonistic effects of nalmefene and naloxone in opiate-induced sedation for emergency department procedures. Am J Emerg Med 7: 155\u2013161.","DOI":"10.1016\/0735-6757(89)90128-9"},{"key":"10.1124\/jpet.104.082966_bib2","doi-asserted-by":"crossref","unstructured":"Berkowitz BA, Ngai SH, Hempstead J, and Spector S (1975) Disposition of naloxone: use of a new radioimmunoassay. J Pharmacol Exp Ther 195: 499\u2013504.","DOI":"10.1016\/S0022-3565(25)30367-8"},{"key":"10.1124\/jpet.104.082966_bib3","doi-asserted-by":"crossref","unstructured":"Bilsky EJ, Bernstein RN, Wang Z, Sad\u00e9e W, and Porreca F (1996) Effects of naloxone and d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J Pharmacol Exp Ther 277: 484\u2013490.","DOI":"10.1016\/S0022-3565(25)12847-4"},{"key":"10.1124\/jpet.104.082966_bib4","doi-asserted-by":"crossref","unstructured":"Blasig J, Herz A, Reinhold K, and Zieglgansberger S (1973) Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia 33: 19\u201338.","DOI":"10.1007\/BF00428791"},{"key":"10.1124\/jpet.104.082966_bib5","doi-asserted-by":"crossref","unstructured":"Buccafusco JJ, Marshall DC, and Turner RM (1984) A comparison of the inhibitory effects of clonidine and guanfacine on the behavioral and autonomic components of morphine withdrawal in rats. Life Sci 35: 1401\u20131408.","DOI":"10.1016\/0024-3205(84)90398-9"},{"key":"10.1124\/jpet.104.082966_bib6","doi-asserted-by":"crossref","unstructured":"Callaerts-Vegh Z, Evans KL, Dudekula N, Cuba D, Knoll BJ, Callaerts PF, Giles H, Shardonofsky FR, and Bond RA (2004) Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA 101: 4948\u20134953.","DOI":"10.1073\/pnas.0400452101"},{"key":"10.1124\/jpet.104.082966_bib7","doi-asserted-by":"crossref","unstructured":"Costa T and Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86: 7321\u20137325.","DOI":"10.1073\/pnas.86.19.7321"},{"key":"10.1124\/jpet.104.082966_bib8","doi-asserted-by":"crossref","unstructured":"Cruz SL, Villarreal JE, and Volkow ND (1996) Further evidence that naloxone acts as an inverse opiate agonist: implications for drug dependence and withdrawal. Life Sci 58: PL381\u2013PL389.","DOI":"10.1016\/0024-3205(96)00250-0"},{"key":"10.1124\/jpet.104.082966_bib9","doi-asserted-by":"crossref","unstructured":"Gbahou F, Rouleau A, Morisset S, Parmentier R, Crochet S, Lin JS, Ligneau X, Tardivel-Lacombe J, Stark H, Schunack W, et al. (2003) Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci USA 100: 11086\u201311091.","DOI":"10.1073\/pnas.1932276100"},{"key":"10.1124\/jpet.104.082966_bib10","doi-asserted-by":"crossref","unstructured":"Gonzalez G, Oliveto A, and Kosten TR (2004) Combating opiate dependence: a comparison among the available pharmacological options. Expert Opin Pharmacother 5: 713\u2013725.","DOI":"10.1517\/eoph.5.4.713.30163"},{"key":"10.1124\/jpet.104.082966_bib11","unstructured":"Jannsen PAJ, Niemegeers CJE, and Dorg JGH (1963) The inhibitory effects of fentanyl and other morphine-like analgesics on the warm water-induced tail withdrawal reflex in rats. Arzneim-Forsch 13: 502\u2013505."},{"key":"10.1124\/jpet.104.082966_bib12","doi-asserted-by":"crossref","unstructured":"Kenakin T (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24: 346\u2013354.","DOI":"10.1016\/S0165-6147(03)00167-6"},{"key":"10.1124\/jpet.104.082966_bib13","doi-asserted-by":"crossref","unstructured":"Kenakin T (2004a) Allosteric modulators: the new generation of receptor antagonist. Mol Interv 4: 222\u2013229.","DOI":"10.1124\/mi.4.4.6"},{"key":"10.1124\/jpet.104.082966_bib14","doi-asserted-by":"crossref","unstructured":"Kenakin T (2004b) Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65: 2\u201311.","DOI":"10.1124\/mol.65.1.2"},{"key":"10.1124\/jpet.104.082966_bib15","doi-asserted-by":"crossref","unstructured":"Kest B, Palmese CA, Hopkins E, Adler M, Juni A, and Mogil JS (2002) Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 115: 463\u2013469.","DOI":"10.1016\/S0306-4522(02)00458-X"},{"key":"10.1124\/jpet.104.082966_bib16","doi-asserted-by":"crossref","unstructured":"Liu JG and Prather PL (2001) Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol Pharmacol 60: 53\u201362.","DOI":"10.1124\/mol.60.1.53"},{"key":"10.1124\/jpet.104.082966_bib17","doi-asserted-by":"crossref","unstructured":"Liu JG and Prather PL (2002) Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors. J Pharmacol Exp Ther 302: 1070\u20131079.","DOI":"10.1124\/jpet.102.035964"},{"key":"10.1124\/jpet.104.082966_bib18","doi-asserted-by":"crossref","unstructured":"Maack C, Cremers B, Flesch M, Hoper A, Sudkamp M, and Bohm M (2000) Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br J Pharmacol 130: 1131\u20131139.","DOI":"10.1038\/sj.bjp.0703400"},{"key":"10.1124\/jpet.104.082966_bib19","doi-asserted-by":"crossref","unstructured":"Maldonado R, Negus S, and Koob GF (1992a) Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. Neuropharmacology 31: 1231\u20131241.","DOI":"10.1016\/0028-3908(92)90051-P"},{"key":"10.1124\/jpet.104.082966_bib20","doi-asserted-by":"crossref","unstructured":"Maldonado R, Stinus L, Gold LH, and Koob GF (1992b) Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J Pharmacol Exp Ther 261: 669\u2013677.","DOI":"10.1016\/S0022-3565(25)11090-2"},{"key":"10.1124\/jpet.104.082966_bib21","doi-asserted-by":"crossref","unstructured":"Porreca F, Mosberg HI, Hurst R, Hruby VJ, and Burks TF (1984) Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther 230: 341\u2013348.","DOI":"10.1016\/S0022-3565(25)21481-1"},{"key":"10.1124\/jpet.104.082966_bib22","doi-asserted-by":"crossref","unstructured":"Preston KL, Bigelow GE, and Liebson IA (1989) Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther 248: 929\u2013937.","DOI":"10.1016\/S0022-3565(25)24168-4"},{"key":"10.1124\/jpet.104.082966_bib23","doi-asserted-by":"crossref","unstructured":"Preston KL, Bigelow GE, and Liebson IA (1990) Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacol Biochem Behav 37: 511\u2013522.","DOI":"10.1016\/0091-3057(90)90021-9"},{"key":"10.1124\/jpet.104.082966_bib24","doi-asserted-by":"crossref","unstructured":"Rouleau A, Ligneau X, Tardivel-Lacombe J, Morisset S, Gbahou F, Schwartz JC, and Arrang JM (2002) Histamine H3-receptor-mediated [35S]GTP-gamma[S] binding: Evidence for constitutive activity of the recombinant and native rat and human H3 receptors. Br J Pharmacol 135: 383\u2013392.","DOI":"10.1038\/sj.bjp.0704490"},{"key":"10.1124\/jpet.104.082966_bib25","doi-asserted-by":"crossref","unstructured":"Sad\u00e9e W, Wang D, and Bilsky EJ (2005) Basal opioid receptor activity, neutral antagonists and therapeutic opportunities. Life Sci 76: 1427\u20131437.","DOI":"10.1016\/j.lfs.2004.10.024"},{"key":"10.1124\/jpet.104.082966_bib26","doi-asserted-by":"crossref","unstructured":"Sep\u00falveda J, Astorga JG, and Contreras E (1999) Riluzole decreases the abstinence syndrome and physical dependence in morphine-dependent mice. Eur J Pharmacol 379: 59\u201362.","DOI":"10.1016\/S0014-2999(99)00503-8"},{"key":"10.1124\/jpet.104.082966_bib27","doi-asserted-by":"crossref","unstructured":"Sterious SN and Walker EA (2003) Potency differences for d-Phe-Cys-Tyr-d-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay. J Pharmacol Exp Ther 304: 301\u2013309.","DOI":"10.1124\/jpet.102.042093"},{"key":"10.1124\/jpet.104.082966_bib28","doi-asserted-by":"crossref","unstructured":"Traynor JR, Clark MJ, and Remmers AE (2002) Relationship between rate and extent of G protein activation: comparison between full and partial opioid agonists. J Pharmacol Exp Ther 300: 157\u2013161.","DOI":"10.1124\/jpet.300.1.157"},{"key":"10.1124\/jpet.104.082966_bib29","doi-asserted-by":"crossref","unstructured":"Valverde O, Mico JA, Maldonado R, and Gibert-Rahola J (1992) Changes in benzodiazepine-receptor activity modify morphine withdrawal syndrome in mice. Drug Alcohol Depend 30: 293\u2013300.","DOI":"10.1016\/0376-8716(92)90064-J"},{"key":"10.1124\/jpet.104.082966_bib30","doi-asserted-by":"crossref","unstructured":"Walker EA, Picker MJ, Granger A, and Dykstra LA (2004) Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine and saline. J Pharmacol Exp Ther 310: 150\u2013158.","DOI":"10.1124\/jpet.103.058503"},{"key":"10.1124\/jpet.104.082966_bib31","doi-asserted-by":"crossref","unstructured":"Wang D, Raehal KM, Bilsky EJ, and Sad\u00e9e W (2001) Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 77: 1590\u20131600.","DOI":"10.1046\/j.1471-4159.2001.00362.x"},{"key":"10.1124\/jpet.104.082966_bib32","doi-asserted-by":"crossref","unstructured":"Wang D, Raehal KM, Lin ET, Lowery JJ, Kieffer BL, Bilsky EJ, and Sad\u00e9e W (2004) Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther 308: 512\u2013520.","DOI":"10.1124\/jpet.103.054049"},{"key":"10.1124\/jpet.104.082966_bib33","doi-asserted-by":"crossref","unstructured":"Wang Z, Bilsky EJ, Porreca F, and Sad\u00e9e W (1994) Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci 54: PL339\u2013PL350.","DOI":"10.1016\/0024-3205(94)90022-1"},{"key":"10.1124\/jpet.104.082966_bib34","doi-asserted-by":"crossref","unstructured":"Way EL, Loh HH, and Shen FH (1969) Simultaneous quantitative assessment of morphine tolerance and physical dependence. J Pharmacol Exp Ther 167: 1\u20138.","DOI":"10.1016\/S0022-3565(25)28247-7"},{"key":"10.1124\/jpet.104.082966_bib35","doi-asserted-by":"crossref","unstructured":"Wells JL, Bartlett JL, Ananthan S, and Bilsky EJ (2001) In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist\/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther 297: 597\u2013605.","DOI":"10.1016\/S0022-3565(24)29575-6"},{"key":"10.1124\/jpet.104.082966_bib36","unstructured":"Yano I and Takemori AE (1977) Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine. Res Commun Chem Pathol Pharmacol 16: 721\u2013734."}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524320178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524320178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.104.082966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T16:27:24Z","timestamp":1739982444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524320178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0022356524320178"],"URL":"https:\/\/doi.org\/10.1124\/jpet.104.082966","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vivo Characterization of 6\u03b2-Naltrexol, an Opioid Ligand with Less Inverse Agonist Activity Compared with Naltrexone and Naloxone in Opioid-Dependent Mice","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.104.082966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}